A new Medicare option for weight loss drugs is coming
NPR
What this means
Could expand access to GLP-1 medications for Medicare patients who previously could not afford coverage.
Daily diabetes tech signal
GlucoseWire curates important diabetes technology, research, access, and care news so readers can quickly understand what changed and why people may care.
The GlucoseWire promise
Three meaningful updates instead of an endless feed of headlines.
Each story focuses on what changed, not medical advice or treatment guidance.
A quick daily scan for diabetes tech, device, access, and care developments.
Today’s signal
Updated daily
NPR
What this means
Could expand access to GLP-1 medications for Medicare patients who previously could not afford coverage.
Drug Delivery Business
What this means
Gives Tandem users access to a longer-wear CGM option, potentially reducing sensor changes and interruptions.
Drug Delivery Business
What this means
Wider visibility of diabetes devices in mainstream media could help normalize wearable diabetes technology and increase public familiarity.
About
GlucoseWire curates important developments in diabetes technology, research, access, and care news to help readers quickly understand what changed and why people may care.
The goal is to reduce noise and surface meaningful updates around devices, automated insulin delivery, glucose monitoring, access, and emerging trends.
GlucoseWire is an editorial and informational project. It does not provide medical advice, treatment recommendations, or clinical guidance.
A cleaner stream of device, research, and access updates from curated sources.
Highlights from diabetes podcasts, including Juicebox Podcast and other high-signal sources.
Follow developments by company, device, category, or topic as the site grows.
Stay updated
A focused summary of meaningful diabetes tech, access, and care developments. Newsletter functionality is coming soon.